New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
Nektar Therapeutics presented new multi-omic biomarker data from the Phase 2b REZOLVE-AD study at EADV Congress 2026, showing rezpegaldesleukin drives Treg-mediated immune changes as early as Week 2. Early biomarker changes were significantly correlated with Week 16 clinical improvement only in rezpegaldesleukin-treated patients (p<0.001), with a 64% mean EASI reduction in the molecular cohort versus 61% in the overall 24 µg/kg Q2W cohort.
Key figures
- Drug Name
- rezpegaldesleukin (REZPEG, NKTR-358)
- Phase Of Trial
- Phase 2b
- Rezpeg patients
- 59
- Placebo patients
- 41
- Phase2b total patients
- 393
- Correlation significance
- p<0.001
- Biomarker substudy patients
- 100
- Easi reduction week16 molecular cohort
- 64%
- Easi reduction week16 overall 24ug q2w cohort
- 61%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.